echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shandong pharmaceutical companies show their power!

    Shandong pharmaceutical companies show their power!

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.
    With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.
     
    After winning 3 major varieties, the second biological drug is coming
     
    Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.
    At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.
     
    Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.
    According to the data of Min.
    com, the domestic market of insulin glargine has continued to expand in recent yea.
    In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.
    A year-on-year increase of 0
     
    Products approved by Lunan Pharmaceutical since the beginning of this year
    Source: MED0 China Drug Evaluation Database
     
    In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.
     
    Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.
     
    It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.
     
    29 varieties have been reviewed! 14 new products on the way
     
    Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.
    7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.
    For exclusive revi.
     
    The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
     
    Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
    Source: MED0 China Drug Evaluation Database
     
    In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.

    Eligibili.

     
    Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.

    Sodium will participate in the biddi.

     
      In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.

     
      In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.

    Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.

     
      Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.

    Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.

    Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.

     
      Lunan Pharmaceutical's new registration classification is under review
      Source: MED0 China Drug Evaluation Database
     
      9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
     
      As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .

    Innovative drugs in immune diseases and other fiel.

     
      In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.

    In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.

     
      Lunan Pharmaceutical's innovative drugs in clinical stage
      Source: MED0 China Drug Evaluation Database
     
      In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.

    Jingfang Mixture comes from ancient prescriptio.

    Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.

    Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.

    This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.

     
      In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.

    Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.

    At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.

     
      In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.

     
      Data source: Minet database
     
      Note: The statistics are as of May 1 If there are any omissions, please correct me!
      Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.

    With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.

     
      After winning 3 major varieties, the second biological drug is coming
     
      Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.

    At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.

     
      Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.

    According to the data of Min.

    com, the domestic market of insulin glargine has continued to expand in recent yea.

    In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.

    A year-on-year increase of 0
     
      Products approved by Lunan Pharmaceutical since the beginning of this year
      Source: MED0 China Drug Evaluation Database
     
      In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.

     
      Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.

     
      It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.

     
      29 varieties have been reviewed! 14 new products on the way
     
      Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.

    7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.

    For exclusive revi.

     
      The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
     
      Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
      Source: MED0 China Drug Evaluation Database
     
      In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.

    Eligibili.

     
      Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.

    Sodium will participate in the biddi.

     
      In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.

     
      In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.

    Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.

     
      Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.

    Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.

    Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.

     
      Lunan Pharmaceutical's new registration classification is under review
      Source: MED0 China Drug Evaluation Database
     
      9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
     
      As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .

    Innovative drugs in immune diseases and other fiel.

     
      In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.

    In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.

     
      Lunan Pharmaceutical's innovative drugs in clinical stage
      Source: MED0 China Drug Evaluation Database
     
      In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.

    Jingfang Mixture comes from ancient prescriptio.

    Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.

    Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.

    This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.

     
      In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.

    Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.

    At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.

     
      In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.

     
      Data source: Minet database
     
      Note: The statistics are as of May 1 If there are any omissions, please correct me!
      Recently, Lunan Pharmaceutical, which started with traditional Chinese medicine, won the company's second listed biological produ.

    With the goal of strengthening biopharmaceuticals, Lunan Pharmaceutical will invest 29 billion yuan in research and development in 2021, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the stage of applying for clinical research, spanning three major fields of traditional Chinese medicine, chemical medicine, and biological medicine; 29 varieties have been reviewed (7 are the first), and 4 varieties are planned to be included in the seventh batch 14 new classification varieties registration applications and 12 varieties consistency evaluation supplementary applications are under revi.

     
      After winning 3 major varieties, the second biological drug is coming
      After winning 3 major varieties, the second biological drug is coming
     
      Recently, the official website of NMPA shows that Lunan Pharmaceutical Group Shandong New Era Pharmaceutical's insulin glargine injection has been approved for marketing, becoming the fifth domestic compa.

    At the same time, this variety is the second biological product of Lunan Pharmaceutical after the long-acting Shengbaiyao (pegylated recombinant human granulocyte-stimulating factor injectio.

     
      Insulin glargine injection belongs to the third-generation insulin, which has the effect of long-acting, no peak in blood concentration, and stable blood sugar reduction of patien.

    According to the data of Min.

    com, the domestic market of insulin glargine has continued to expand in recent yea.

    In 2021, the terminal sales in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 3 billion yu.

    A year-on-year increase of 0
    hospital hospital hospital
     
      Products approved by Lunan Pharmaceutical since the beginning of this year
      Source: MED0 China Drug Evaluation Database
     
      In addition to insulin glargine injection, Lunan Pharmaceutical has also approved two varieties of enoxaparin sodium injection and metformin hydrochloride sustained-release tablets since the beginning of this year, which are deemed to have passed the consistency evaluati.

     
      Among them, enoxaparin sodium injection is the market leader of low molecular weight heparin preparations, with terminal sales of more than 6 billion yuan in Chinese public medical institutions in 202 Enoxaparin sodium injection is expected to be included in the eighth batch of centralized procurement, and Lunan Pharmaceutical is the fifth company that has passed the evaluatio.

    enterprise enterprise enterprise
     
      It is worth mentioning that insulin glargine injection, enoxaparin sodium injection, and metformin hydrochloride sustained-release tablets have performed well in terminal sales in Chinese public medical institutions in recent years, and Lunan Pharmaceutical is expected to take a sha.

     
      29 varieties have been reviewed! 14 new products on the way
      29 varieties have been reviewed! 14 new products on the way
     
      Up to now, 29 varieties (37 specifications) of Lunan Pharmaceutical have passed/deemed to pass the consistency evaluati.

    7 varieties are the first to review, including 5 varieties including tirofiban hydrochloride injection concentrated solution, axitinib tablets, etodolac capsules, ketorolac tromethamine tablets, and epirubicin hydrochloride injecti.

    For exclusive revi.

     
      The 29 reviewed varieties are mainly concentrated in digestive system and metabolizing drugs (6), cardiovascular and cerebrovascular drugs (6), anti- tumor and immunomodulators (
    tumor tumor tumor
     
      Lunan Pharmaceutical passed/deemed to pass the consistency evaluation varieties
      Source: MED0 China Drug Evaluation Database
     
      In the first five batches of centralized procurement carried out by the state, 4 varieties of Lunan Pharmaceutical's Cetirizine Hydrochloride Tablets, Mosapride Citrate Tablets, Isosorbide Mononitrate Sustained-Release Tablets, and Rivaroxaban Tablets were obtain.

    Eligibili.

     
      Among the seventh batch of varieties to be collected, Lunan Pharmaceutical's Milrinone Injection, Tirofiban Hydrochloride Injection/Tirofiban Hydrochloride Concentrated Solution for Injection, Isosorbide Mononitrate Tablets, and Omeprazole for Injecti.

    Sodium will participate in the biddi.

     
      In terms of supplementary applications for consistency evaluation, Lunan Pharmaceutical has 12 varieties (16 acceptance numbers) in the state of “under review and approval”, including epirubicin hydrochloride for injection, imipenem and cilastatin sodium for injection, and Lilistat Capsules, Cetylpyridinium Chloride Lozenges,e.

     
      In terms of new registration classification applications, Lunan Pharmaceutical has 14 varieties (18 acceptance numbers) marketing applications under review, and will be deemed to have passed the consistency evaluation after being approved for producti.

    Among them, there are 7 varieties of anti-tumor and immunomodulatory agen.

     
      Among the 14 varieties to be approved, two varieties, Sapropterin Hydrochloride Tablets and Vonola Fumarate Raw Tablets, have not been approved as generic drugs in the domestic mark.

    Imitation; Dasatinib tablets have been approved by Chia Tai Tianqing and CS.

    Currently, only Lunan Pharmaceutical is under review for this product, and it is expected to become the third domestic compa.

     
      Lunan Pharmaceutical's new registration classification is under review
     
      Source: MED0 China Drug Evaluation Database
     
      9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
      9 innovative drugs are in full swing! Across traditional Chinese medicine, chemical medicine, biological medicine
     
      As a comprehensive pharmaceutical group integrating the production, research and sales of pharmaceuticals, chemical drugs and biological products, Lunan Pharmaceutical Group aims to "maintain the advantages of chemical pharmaceuticals, vigorously develop traditional Chinese medicine, and strengthen biopharmaceuticals .

    Innovative drugs in immune diseases and other fiel.

    disease disease disease
     
      In recent years, Lunan Pharmaceutical has continued to increase investment in scientific resear.

    In 2021, R&D investment will be 29 billion yuan, a year-on-year increase of 3
    At present, Lunan Pharmaceutical has 9 innovative drugs in the clinical research sta.

     
      Lunan Pharmaceutical's innovative drugs in clinical stage
      Source: MED0 China Drug Evaluation Database
     
      In the field of Chinese patent medicines, Jingfang Mixture has been approved for clinical use for urticaria such as skin rash and itchi.

    Jingfang Mixture comes from ancient prescriptio.

    Lunan Pharmaceutical uses modern technology to develop Jingfangbaidu Powder into a finished medici.

    Currently, there are two formulations (Jingfang Granule/Mixture, trade name Qidal.

    This product is clinically used for four-season colds, and has been recommended by the local government for the treatment of new coronary pneumonia evil invading lung health certifica.

     
      In the field of chemical drugs, Lunan Pharmaceutical's class 1 new drug LL-10 has been approved for clinical use, and class 2 improved new drugs, vornorasan fumarate injection and mosapride citrate injection, are exclusively deployed in Chi.

    Among them, LL-10 injection is a new type of long-acting local anesthetic, intended for local anesthesia and analges.

    At present, there are only a handful of Class 1 new drugs under development in the field of local anesthesia in Chi.

     
      In the field of biological products, Lunan Pharmaceutical's long-acting Baisheng medicine has been put on the market, and insulin glargine has been approved for production; the biosimilar recombinant anti-CD20 human-mouse chimeric monoclonal antibody injection is in phase III clinical; 4 new drugs of class 1 PD-1 monoclonal antibody, BCMA/CD3 double antibody, CD47 monoclonal antibody, LNF1904 are in clinical progress; more than 20 new class 1 biological drugs are being developed, and strive to launch a biological product every year in the next 3-5 yea.

     
      Data source: Minet database
     
      Note: The statistics are as of May 1 If there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.